Biotech RadarJobs updated

COMPANY

Idience

idience.com ↗

Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: Gastric Cancer Homologous Recombination Repair Gene Mutation Homologous Recombination Deficiency NOV140101 (IDX-1197) IDX-1197

4Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Food Effect Study of IDX-1197 in Healthy Subjects source ↗
  2. Trial start Phase 1/Phase 2: Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer source ↗
  3. Trial start Phase 1/Phase 2: Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) source ↗
  4. Trial start Phase 1: Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors source ↗

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT04725994Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerPhase 1/Phase 2Active, not recruitingJun 28, 2021Jul 31, 2026 (estimated)
NCT03317743Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid TumorsPhase 1CompletedAug 29, 2017Dec 8, 2020 (actual)
NCT04174716Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)Phase 1/Phase 2CompletedNov 6, 2019Mar 31, 2023 (actual)
NCT05202912Food Effect Study of IDX-1197 in Healthy SubjectsPhase 1CompletedJan 16, 2022Jul 23, 2022 (actual)
Feedback